Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registry

19 Feb 2025

Abstract excerpt

Background: VEXAS syndrome, a recently identified systemic autoinflammatory disorder, poses new diagnostic and management challenges. Based on experience with other autoinflammatory diseases, anti-interleukin (IL)-1, anti-IL-6, anti-tumor necrosis factor (TNF) biotechnological agents, and Janus kinase inhibitors (JAKis) have been widely employed in VEXAS patients. The aim of this study is to evaluate the global...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Congenital Ear and Nasal Anomalies
Share to Osteomyelitis and Bone Disorders Research
Share to Otitis Media and Relapsing Polychondritis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40046741
DOI: 10.3389/fphar.2025.1462254

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registryPMID 40046741Read ↗

Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry.Semantic proximity Read ↗

VEXAS Syndrome—ReviewSemantic proximity Read ↗

Clinical Challenges of Emerging Acquired Autoinflammatory Diseases, Including VEXAS Syndrome.Semantic proximity Read ↗

Untitled literature recordSemantic proximity Read ↗

How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies.Semantic proximity Read ↗

VEXAS syndrome: an adult-onset autoinflammatory disorder with underlying somatic mutation.Semantic proximity Read ↗

Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX.Semantic proximity Read ↗

VEXAS syndrome, immunodeficiency, and risk of infectionSemantic proximity Read ↗

VEXAS syndrome in adults: A narrative review of genomic pathogenesis, multisystem phenotypes, diagnostic algorithms, and emerging therapeutic strategies.Semantic proximity Read ↗

Improving Diagnosis and Clinical Management of Acquired Systemic Autoinflammatory DiseasesSemantic proximity Read ↗

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.Semantic proximity Read ↗

Navigating therapeutic challenges in VEXAS syndrome: exploring IL-6 and JAK inhibitors at the forefront.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.